The past decade has seen significant advances in stroke prevention. These advances
include new antithrombotic agents, new options for dyslipidemia treatment, and novel …

Introduction Cardioembolic stroke, associated to nonvalvular atrial fibrillation (NVAF),
accounts for approximately one in every four strokes. Cardioembolic stroke has a bad …

Background: Although apixaban and rivaroxaban are commonly used in patients with atrial
fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 …

Background We sought to examine outcomes of direct oral anticoagulants (DOACs) versus
warfarin in atrial fibrillation with valve repair/replacement. Methods and Results Two atrial …

Importance The temporal trend in adverse events regarding stroke prevention for
nonvalvular atrial fibrillation (NVAF) in the direct oral anticoagulant (DOAC) era was rarely …

Background To investigate risks of hospitalization for upper gastrointestinal bleeding (UGIB)
in H. pylori‐eradicated patients newly started on warfarin or direct oral anti‐coagulants …

Background Hemorrhage is a potential and serious adverse drug reaction, especially for
geriatric patients with long-term administration of rivaroxaban. It is essential to establish an …

Background Active surveillance pharmacovigilance is an emerging approach to identify
medications with unanticipated effects. We previously developed a framework called …

Gastrointestinal bleeding (GIB) is the most common type of bleeding occurring in patients on
oral anticoagulation. A meta-analysis of the landmark randomized controlled trials (RCTs) …

Background Headache, often migrainous, is common in patients with antiphospholipid
antibodies, whether or not they meet Sydney criteria for a definite diagnosis of Hughes …